| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human GIPC1 recombinant protein (Position: H66-Y333) was used as the immunogen for the GIPC1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
GIPC1 Antibody / PDZ domain-containing protein GIPC1 is a anti-GIPC1 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), Flow cytometry (FACS), ELISA with listed reactivity in Human, Mouse, Rat. Reported localization: Cytoplasm, cell membrane, nucleus.
Key elements and design rationale
- Target: GIPC1
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, IHC, ICC, IF, FACS, ELISA
Biological background
Functionally, GIPC1 antibody identifies a 333-amino-acid protein that contains a central PDZ domain responsible for binding the C-terminal motifs of target proteins such as TGFbeta receptor III, GLUT1, and neuropilin-1. GIPC1 participates in endocytic recycling and intracellular trafficking of these receptors, thereby modulating cellular responses to growth factors, adhesion molecules, and hormones. Additionally, GIPC1 acts as a linker between membrane receptors and the actin cytoskeleton via interactions with myosin VI, regulating cell polarity and motility.
The GIPC1 gene is located on chromosome 19p13.12 and is expressed ubiquitously, with high levels found in epithelial, neuronal, and endothelial tissues. Its expression is regulated during development and by extracellular stimuli such as growth factors and oxidative stress. GIPC1 is essential for maintaining proper vesicle transport and receptor localization in diverse cell types.
Pathologically, altered GIPC1 expression has been implicated in cancer progression, angiogenesis, and neurological disorders. Overexpression in breast, pancreatic, and gastric cancers enhances tumor cell proliferation and migration by stabilizing growth factor receptor signaling. In neurons, dysregulated GIPC1 may disrupt synaptic vesicle trafficking and signaling. Research using GIPC1 antibody supports studies in receptor trafficking, cancer signaling, and cytoskeletal regulation.
GIPC1 antibody is validated for western blotting, immunohistochemistry, and immunofluorescence to detect adaptor proteins involved in signal transduction.
Structurally, PDZ domain-containing protein GIPC1 includes an N-terminal GH1 domain for dimerization, a central PDZ domain for C-terminal binding to target proteins, and a C-terminal GH2 domain for myosin VI interaction. This modular structure enables GIPC1 to act as a versatile scaffold that coordinates endocytic transport and receptor-mediated signaling. This antibody enables exploration of GIPC1's role in intracellular trafficking, cancer progression, and signal compartmentalization.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
